Sponsor & Developer Portfolio
Novartis Pharmaceuticals
Clinical development pipeline, platform architecture, and registered trial tracking for Novartis Pharmaceuticals vaccine candidates.
2
Candidates
2
Target Diseases
2
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 1 Phase 2 Clinical Trial: 1
Platform Technologies
mRNA: 1 Biological (unspecified platform): 1
Target Pathogens & Indications
COVID-19 Immunoglobulin A Nephropathy (IgAN)
Vaccine Pipeline Candidates (2)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals
mRNA COVID-19 vaccine
Target: COVID-19
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2023-04-14 (registry estimate)
Phase 2 Clinical Trial
ctgov-zigakibart-novartis-pharmaceuticals
zigakibart
Target: Immunoglobulin A Nephropathy (IgAN)
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2030-07-12 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.